FibroGen, Inc (FGEN) News
Filter FGEN News Items
FGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FGEN News Highlights
- For FGEN, its 30 day story count is now at 6.
- Over the past 25 days, the trend for FGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
Latest FGEN News From Around the Web
Below are the latest news stories about FIBROGEN INC that investors may wish to consider to help them evaluate FGEN as an investment opportunity.
FibroGen (NASDAQ:FGEN investor five-year losses grow to 60% as the stock sheds US$145m this past weekFibroGen, Inc. ( NASDAQ:FGEN ) shareholders should be happy to see the share price up 20% in the last quarter. But that... |
FibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Call TranscriptFibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Thank you for standing by, and welcome to FibroGen’s Fourth Quarter and Full Year 2022 Financial Results Earnings Call. . I would now like to hand the call over to your host, Mike Tung. Please go ahead. Michael Tung: Thank you, Latif, and […] |
Q4 2022 FibroGen Inc Earnings CallQ4 2022 FibroGen Inc Earnings Call |
FibroGen (FGEN) Reports Q4 Loss, Tops Revenue EstimatesFibroGen (FGEN) delivered earnings and revenue surprises of 26.32% and 43.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
FibroGen Reports Fourth Quarter and Full Year 2022 Financial ResultsTopline Data from Five Pivotal Phase 3 Trials in 2023Total Company Revenue $140.7 Million in 2022Continued Strong Roxadustat Volume Growth in China SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2022 and provided an update on the company’s recent developments. “We are proud of the significant progress advancing our clinical pipeline in 2022 and excited and well-prepared to deliver results from f |
FibroGen to Present at Cowen’s 43rd Annual Health Care ConferenceSAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen’s 43rd Annual Health Care Conference to be held in Boston on March 5 - 8, 2023. Details of the presentations are as follows: Panel Information:Date: Wednesday, March 8, 2023Panel topic: Respiratory/Infections Time: 10:30 AM Eastern Time A live audio webcast of the event will be available to investors |
Should You Buy FibroGen (FGEN) Ahead of Earnings?FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
4 Drug, Biotech Stocks Poised to Beat Q4 Earnings EstimatesWe look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter. |
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out forImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |